384 related articles for article (PubMed ID: 28267887)
1. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
[TBL] [Abstract][Full Text] [Related]
2. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis.
Nielsen MJ; Thorburn D; Leeming DJ; Hov JR; Nygård S; Moum B; Saffioti F; Gilja OH; Boberg KM; Mazza G; Røsjø H; Pinzani M; Karlsen TH; Karsdal MA; Vesterhus M
Aliment Pharmacol Ther; 2018 Jul; 48(2):179-189. PubMed ID: 29851098
[TBL] [Abstract][Full Text] [Related]
3. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.
Vesterhus M; Hov JR; Holm A; Schrumpf E; Nygård S; Godang K; Andersen IM; Naess S; Thorburn D; Saffioti F; Vatn M; Gilja OH; Lund-Johansen F; Syversveen T; Brabrand K; Parés A; Ponsioen CY; Pinzani M; Färkkilä M; Moum B; Ueland T; Røsjø H; Rosenberg W; Boberg KM; Karlsen TH
Hepatology; 2015 Jul; 62(1):188-97. PubMed ID: 25833813
[TBL] [Abstract][Full Text] [Related]
4. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease.
Irvine KM; Wockner LF; Shanker M; Fagan KJ; Horsfall LU; Fletcher LM; Ungerer JP; Pretorius CJ; Miller GC; Clouston AD; Lampe G; Powell EE
Liver Int; 2016 Mar; 36(3):370-7. PubMed ID: 26104018
[TBL] [Abstract][Full Text] [Related]
5. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
[TBL] [Abstract][Full Text] [Related]
6. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients.
Fernandes FF; Ferraz ML; Andrade LE; Dellavance A; Terra C; Pereira G; Pereira JL; Campos F; Figueiredo F; Perez RM
J Clin Gastroenterol; 2015 Mar; 49(3):235-41. PubMed ID: 24714186
[TBL] [Abstract][Full Text] [Related]
7. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C.
Catanzaro R; Milazzo M; Arona S; Sapienza C; Vasta D; Arcoria D; Marotta F
Hepatobiliary Pancreat Dis Int; 2013 Oct; 12(5):500-7. PubMed ID: 24103280
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
Tanwar S; Trembling PM; Hogan BJ; Srivastava A; Parkes J; Harris S; Grant P; Nastouli E; Ocker M; Wehr K; Herold C; Neureiter D; Schuppan D; Rosenberg WM
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):289-296. PubMed ID: 27906753
[TBL] [Abstract][Full Text] [Related]
10. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
[TBL] [Abstract][Full Text] [Related]
11. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
Weismüller TJ; Trivedi PJ; Bergquist A; Imam M; Lenzen H; Ponsioen CY; Holm K; Gotthardt D; Färkkilä MA; Marschall HU; Thorburn D; Weersma RK; Fevery J; Mueller T; Chazouillères O; Schulze K; Lazaridis KN; Almer S; Pereira SP; Levy C; Mason A; Naess S; Bowlus CL; Floreani A; Halilbasic E; Yimam KK; Milkiewicz P; Beuers U; Huynh DK; Pares A; Manser CN; Dalekos GN; Eksteen B; Invernizzi P; Berg CP; Kirchner GI; Sarrazin C; Zimmer V; Fabris L; Braun F; Marzioni M; Juran BD; Said K; Rupp C; Jokelainen K; Benito de Valle M; Saffioti F; Cheung A; Trauner M; Schramm C; Chapman RW; Karlsen TH; Schrumpf E; Strassburg CP; Manns MP; Lindor KD; Hirschfield GM; Hansen BE; Boberg KM;
Gastroenterology; 2017 Jun; 152(8):1975-1984.e8. PubMed ID: 28274849
[TBL] [Abstract][Full Text] [Related]
12. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
de Vries EM; de Krijger M; Färkkilä M; Arola J; Schirmacher P; Gotthardt D; Goeppert B; Trivedi PJ; Hirschfield GM; Ytting H; Vainer B; Buuren HR; Biermann K; Harms MH; Chazouilleres O; Wendum D; Kemgang AD; Chapman RW; Wang LM; Williamson KD; Gouw AS; Paradis V; Sempoux C; Beuers U; Hübscher SG; Verheij J; Ponsioen CY
Hepatology; 2017 Mar; 65(3):907-919. PubMed ID: 27880989
[TBL] [Abstract][Full Text] [Related]
13. Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis.
Goet JC; Floreani A; Verhelst X; Cazzagon N; Perini L; Lammers WJ; de Vries AC; van der Meer AJ; van Buuren HR; Hansen BE
J Hepatol; 2019 Nov; 71(5):992-999. PubMed ID: 31278949
[TBL] [Abstract][Full Text] [Related]
14. Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients.
Omran D; Yosry A; Darweesh SK; Nabeel MM; El-Beshlawey M; Saif S; Fared A; Hassany M; Zayed RA
Clin Exp Med; 2018 Feb; 18(1):45-50. PubMed ID: 28567544
[TBL] [Abstract][Full Text] [Related]
15. Appraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis.
Gunes Yegin E; Durusoy SS; Ture Ozdemir F; Kombak EF; Ataizi-Celikel C; Ozdogan OC
Ann Hepatol; 2019; 18(6):833-840. PubMed ID: 31558418
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.
Parkes J; Guha IN; Roderick P; Harris S; Cross R; Manos MM; Irving W; Zaitoun A; Wheatley M; Ryder S; Rosenberg W
J Viral Hepat; 2011 Jan; 18(1):23-31. PubMed ID: 20196799
[TBL] [Abstract][Full Text] [Related]
17. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis.
de Vries EM; Wang J; Williamson KD; Leeflang MM; Boonstra K; Weersma RK; Beuers U; Chapman RW; Geskus RB; Ponsioen CY
Gut; 2018 Oct; 67(10):1864-1869. PubMed ID: 28739581
[TBL] [Abstract][Full Text] [Related]
18. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan.
Tanaka A; Tazuma S; Nakazawa T; Isayama H; Tsuyuguchi T; Inui K; Takikawa H
J Hepatobiliary Pancreat Sci; 2017 Apr; 24(4):217-225. PubMed ID: 28103424
[TBL] [Abstract][Full Text] [Related]
19. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
Fossdal G; Mjelle AB; Wiencke K; Bjørk I; Gilja OH; Folseraas T; Karlsen TH; Rosenberg W; Giil LM; Vesterhus M
JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
[TBL] [Abstract][Full Text] [Related]
20. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis.
Saffioti F; Roccarina D; Vesterhus M; Hov JR; Rosenberg W; Pinzani M; Pereira SP; Boberg KM; Thorburn D
Eur J Clin Invest; 2019 May; 49(5):e13088. PubMed ID: 30762236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
